Operation manual for control of production, preclinical toxicology and phase I trials of anti-tumour antibodies and drug antibody conjugates. Prepared by a Joint Committee of the: Cancer Research Campaign National Institute for Biological Standards and Control.
出版信息
Br J Cancer. 1986 Sep;54(3):557-68. doi: 10.1038/bjc.1986.209.
Abstract
摘要
相似文献
1
Operation manual for control of production, preclinical toxicology and phase I trials of anti-tumour antibodies and drug antibody conjugates. Prepared by a Joint Committee of the: Cancer Research Campaign National Institute for Biological Standards and Control.抗肿瘤抗体及药物抗体偶联物的生产控制、临床前毒理学和I期试验操作手册。由癌症研究运动国家生物标准与控制研究所联合委员会编写。
Br J Cancer. 1986 Sep;54(3):557-68. doi: 10.1038/bjc.1986.209.
2
In vitro and in vivo effects of anti-tumor antibody covalently coupled to a chemotactic peptide.与趋化肽共价偶联的抗肿瘤抗体的体外和体内效应
Agents Actions Suppl. 1983;12:234-50. doi: 10.1007/978-3-0348-9352-7_14.
3
Technology evaluation: CC49 humanized radioimmunoconjugates, National Cancer Institute.技术评估：CC49人源化放射免疫缀合物，美国国立癌症研究所
Curr Opin Mol Ther. 2003 Aug;5(4):428-32.
4
Current status of antibody-toxin conjugates for tumor therapy.用于肿瘤治疗的抗体-毒素偶联物的现状
Targeted Diagn Ther. 1990;3:189-213.
5
Oncostatic-antibody complexes in chemotherapy.化疗中的肿瘤生长抑制抗体复合物
Cancer Chemother Pharmacol. 1980;4(1):29-32. doi: 10.1007/BF00255454.
6
Monoclonal antibodies for radioimmunodetection of tumours and for targeting.用于肿瘤放射免疫检测和靶向治疗的单克隆抗体。
Bull Cancer. 1983;70(2):132-6.
7
Serotherapy of cancer.癌症血清疗法。
Semin Oncol. 1989 Jun;16(3):180-98.
8
Suppression of tumour growth in mice by a drug-antibody conjugate using a novel approach to linkage.一种采用新型连接方法的药物-抗体偶联物对小鼠肿瘤生长的抑制作用。
Nature. 1975 Jun 5;255(5508):487-8. doi: 10.1038/255487a0.
9
Monoclonal antibody administration. Current clinical pharmacokinetic status and future trends.单克隆抗体给药。当前临床药代动力学状况及未来趋势。
Clin Pharmacokinet. 1992 Aug;23(2):85-9. doi: 10.2165/00003088-199223020-00001.
10
Macromolecule-drug conjugates in targeted cancer chemotherapy.靶向癌症化疗中的大分子-药物偶联物
Crit Rev Ther Drug Carrier Syst. 1984;1(1):1-38.
引用本文的文献
1
Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: results of a phase I study.晚期结直肠癌患者经皮内重复接种抗癌胚抗原鼠单克隆抗体PR1A3后的免疫反应：一项I期研究结果
Int J Colorectal Dis. 2005 Sep;20(5):403-14. doi: 10.1007/s00384-004-0726-x. Epub 2005 Apr 30.
2
Tumour targeting of humanised cross-linked divalent-Fab' antibody fragments: a clinical phase I/II study.人源化交联二价Fab'抗体片段的肿瘤靶向性：一项临床I/II期研究。
Br J Cancer. 2002 May 6;86(9):1401-10. doi: 10.1038/sj.bjc.6600198.
3
Cancer Research UK procedures in manufacture and toxicology of radiotracers intended for pre-phase I positron emission tomography studies in cancer patients.英国癌症研究中心针对癌症患者I期前正电子发射断层扫描研究用放射性示踪剂的生产与毒理学程序。
Br J Cancer. 2002 Apr 8;86(7):1052-6. doi: 10.1038/sj.bjc.6600212.
4
Of mice and men..《人鼠之间》
Eur J Nucl Med. 1992;19(6):385-6. doi: 10.1007/BF00177363.
本文引用的文献
1
Predicting anticancer drug effects in man from laboratory animal studies.从实验室动物研究预测抗癌药物对人类的疗效。
J Chronic Dis. 1962 Mar;15:223-8. doi: 10.1016/0021-9681(62)90003-6.
2
Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.抗癌药物在小鼠、大鼠、仓鼠、狗、猴和人类中毒性的定量比较。
Cancer Chemother Rep. 1966 May;50(4):219-44.
Zotero 插件